Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status

•Celecoxib, an anti Cox2, does not improve pathological complete response (pCR) nor outcome in HER2 negative breast cancer patients receiving sequential neoadjuvant chemotherapy.•Long term outcome of luminal B breast cancer can be worse than triple negative breast cancer while HER2 positive breast cancer patients have a better prognostic than other subtypes with the addition of trastuzumab in neoadjuvant or adjuvant setting.